Legato Merger Corp. III (LEGT) Prices $175M IPO
by Marlena Haddad on 2024-02-05 at 5:11pm

Legato Merger Corp. III (NYSE: LEGT) announced the pricing of its $175 million IPO this evening. Its units are expected to begin trading on the NYSE American under the symbol “LEGT U” on Tuesday, February 6, 2024. After the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on the NYSE under the symbols “LEGT” and “LEGT WS”, respectively.

Legato III intends to focus on target businesses in the infrastructure, engineering and construction, industrial and renewables industries.

The Company’s management team is comprised of Gregory Monahan, Chief Executive Officer and Director, Eric S. Rosenfeld, Chief SPAC Officer, Adam Jaffe, Chief Financial Officer, Secretary and Director, Brian Pratt, Director and Non-Executive Chairman of the Board, David D. Sgro, Director and Non-Executive Vice Chairman of the Board, and Adam Semler and John Ing, each a Director of the Company.

Total SPAC deal count for 2024 year-to-date is now 2. This offering is expected to close on Wednesday, February 7, 2024.


BTIG, LLC is acting as the sole book-running manager for the offering, with Craig-Hallum Capital Group LLC as co-manager.  Graubard Miller is serving as Issuer’s Counsel with Loeb & Loeb LLP serving as Underwriter’s Counsel. WithumSmith+Brown, PC serves as auditor. Equiniti Trust Company, LLC is acting as trustee.

Recent Posts
by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

by Nicholas Alan Clayton on 2024-04-16 at 7:58am

At the SPAC of Dawn Ever since Digital World announced its combination with Trump Media (NASDAQ:DJT) back in October 2021, it was clear that SPACworld and the Trump show were set to be intertwined for quite some time. And, although not every headline has a bearing on the wider SPAC world, Trump Media’s post-close rise...

by Nicholas Alan Clayton on 2024-04-15 at 3:47pm

AltC (NYSE:ALCC) has reportedly been taking the pitch deck for its combination with nuclear fission firm Oklo on the road in recent weeks, which has generated the rare result of a SPAC trading significantly above its trust value still well before completing its deal. The SPAC has an estimated $10.59 per share in its trust...

by Nicholas Alan Clayton on 2024-04-15 at 9:35am

Trump Media (NASDAQ:DJT) is down about -15% in the pre-market following the filing of its first S-1 since closing its combination with Digital World, and this includes the issuance of the 21,491,251 shares. Of these, 14,375,000 are to be made available for those exercising warrants while the rest would go out to note holders from...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved